_id stringlengths 6 8 | title stringlengths 10 234 | text stringlengths 90 9.94k | query stringlengths 6 216 | embedding_ada listlengths 1.54k 1.54k | embedding_small listlengths 1.54k 1.54k | embedding_large listlengths 1.54k 1.54k |
|---|---|---|---|---|---|---|
MED-10 | Statin Use and Breast Cancer Survival: A Nationwide Cohort Study from Finland | Recent studies have suggested that statins, an established drug group in the prevention of cardiovascular mortality, could delay or prevent breast cancer recurrence but the effect on disease-specific mortality remains unclear. We evaluated risk of breast cancer death among statin users in a population-based cohort of breast cancer patients. The study cohort included all newly diagnosed breast cancer patients in Finland during 1995–2003 (31,236 cases), identified from the Finnish Cancer Registry. Information on statin use before and after the diagnosis was obtained from a national prescription database. We used the Cox proportional hazards regression method to estimate mortality among statin users with statin use as time-dependent variable. A total of 4,151 participants had used statins. During the median follow-up of 3.25 years after the diagnosis (range 0.08–9.0 years) 6,011 participants died, of which 3,619 (60.2%) was due to breast cancer. After adjustment for age, tumor characteristics, and treatment selection, both post-diagnostic and pre-diagnostic statin use were associated with lowered risk of breast cancer death (HR 0.46, 95% CI 0.38–0.55 and HR 0.54, 95% CI 0.44–0.67, respectively). The risk decrease by post-diagnostic statin use was likely affected by healthy adherer bias; that is, the greater likelihood of dying cancer patients to discontinue statin use as the association was not clearly dose-dependent and observed already at low-dose/short-term use. The dose- and time-dependence of the survival benefit among pre-diagnostic statin users suggests a possible causal effect that should be evaluated further in a clinical trial testing statins’ effect on survival in breast cancer patients. | how many statins are used during a cancer diagnosis | [
-0.010449815541505814,
-0.014972485601902008,
0.03185196593403816,
-0.029429567977786064,
-0.017046986147761345,
0.019804397597908974,
-0.02128618396818638,
0.01257585734128952,
-0.02211083099246025,
-0.010295194573700428,
0.005969022400677204,
0.01101031806319952,
0.007524898275732994,
0.... | [
-0.009327104315161705,
-0.025833727791905403,
0.02013818547129631,
0.03617975860834122,
0.0036080479621887207,
-0.005026708357036114,
-0.009081517346203327,
-0.026439858600497246,
0.010476663708686829,
0.006547261495143175,
0.021287744864821434,
-0.017640506848692894,
-0.046274978667497635,
... | [
-0.009013567119836807,
0.0031939211767166853,
-0.03251710161566734,
-0.0015930820954963565,
-0.017468634992837906,
-0.019749175757169724,
0.022448591887950897,
-0.0006690362934023142,
0.003191981930285692,
0.028436951339244843,
-0.009742720052599907,
-0.01801162026822567,
0.02952292375266552... |
MED-14 | Statin use after diagnosis of breast cancer and survival: a population-based cohort study. | "BACKGROUND: Preclinical studies have shown that statins, particularly simvastatin, can prevent grow(...TRUNCATED) | which statin to use after cancer diagnosis | [-0.009840613231062889,-0.016248902305960655,0.01857568323612213,-0.040056630969047546,-0.0239362791(...TRUNCATED) | [0.01901252008974552,-0.0024097454734146595,0.01007033046334982,0.02455369010567665,-0.0078361667692(...TRUNCATED) | [-0.015796935185790062,0.013648666441440582,-0.027340298518538475,0.04116082563996315,0.003222402883(...TRUNCATED) |
MED-118 | Alkylphenols in human milk and their relations to dietary habits in central Taiwan. | "The aims of this study were to determine the concentrations of 4-nonylphenol (NP) and 4-octylphenol(...TRUNCATED) | what is the op concentration in human milk | [0.032275911420583725,-0.0026452387683093548,-0.004574197344481945,-0.0389389805495739,-0.0195494480(...TRUNCATED) | [0.009051091969013214,0.02364460937678814,-0.005833373870700598,0.010076613165438175,0.0289450585842(...TRUNCATED) | [-0.03240354731678963,-0.06176375597715378,-0.016401993110775948,0.011156238615512848,0.029984893277(...TRUNCATED) |
MED-301 | Methylmercury: A Potential Environmental Risk Factor Contributing to Epileptogenesis | "Epilepsy or seizure disorder is one of the most common neurological diseases in humans. Although ge(...TRUNCATED) | what is methylmercury used for | [0.00022365331824403256,0.013692048378288746,0.005741399712860584,-0.03055906482040882,-0.0260082762(...TRUNCATED) | [0.012378931045532227,0.0026896342169493437,0.016589751467108727,0.06146475672721863,-0.014131602831(...TRUNCATED) | [-0.021844446659088135,-0.016723237931728363,-0.00901876576244831,0.00008125811291392893,0.005706597(...TRUNCATED) |
MED-306 | "Sensitivity of Continuous Performance Test (CPT) at Age 14 Years to Developmental Methylmercury Exp(...TRUNCATED) | "Hit Reaction Time latencies (HRT) in the Continuous Performance Test (CPT) measure the speed of vis(...TRUNCATED) | how long for methylmercury test | [-0.01942918449640274,0.011835002340376377,0.020418258383870125,-0.03330330178141594,-0.025688797235(...TRUNCATED) | [0.01148336473852396,0.027272989973425865,0.07952733337879181,0.033190950751304626,-0.00919172819703(...TRUNCATED) | [0.011842073872685432,-0.020610632374882698,-0.013523467816412449,0.0029831179417669773,-0.016868175(...TRUNCATED) |
MED-329 | Phosphate is a vascular toxin. | "Elevated phosphate (P) levels are seen in advanced renal failure and, together with dysregulated ca(...TRUNCATED) | what does elevated p levels mean in a patient | [0.017938900738954544,-0.022756554186344147,0.020210640504956245,-0.024532165378332138,-0.0211637262(...TRUNCATED) | [0.0029143241699784994,0.04303869232535362,0.05229838937520981,0.08598289638757706,-0.00159003399312(...TRUNCATED) | [-0.0036987808998674154,0.01772659458220005,-0.018537914380431175,0.0333406925201416,0.0266358144581(...TRUNCATED) |
MED-330 | Dietary Phosphorus Acutely Impairs Endothelial Function | "Excessive dietary phosphorus may increase cardiovascular risk in healthy individuals as well as in (...TRUNCATED) | causes of hyperphosphorus in the intestines | [0.00726856105029583,-0.005253514274954796,0.01618579588830471,-0.022113174200057983,-0.013006210327(...TRUNCATED) | [-0.016148654744029045,0.04054008796811104,0.008265236392617226,0.029085546731948853,-0.022055603563(...TRUNCATED) | [-0.01563315838575363,0.015081570483744144,-0.010305981151759624,0.03977238014340401,0.0181443337351(...TRUNCATED) |
MED-332 | "Public health impact of dietary phosphorus excess on bone and cardiovascular health in the general (...TRUNCATED) | "This review explores the potential adverse impact of the increasing phosphorus content in the Ameri(...TRUNCATED) | what does a lack of phosphorus mean in our diet | [0.024634238332509995,-0.016758419573307037,0.032114993780851364,-0.03147779032588005,-0.00145760015(...TRUNCATED) | [0.02433665283024311,0.04127582162618637,0.05124634504318237,0.07817747443914413,-0.0011685881763696(...TRUNCATED) | [0.009039529599249363,0.03700026869773865,-0.028307108208537102,0.06552470475435257,0.03640261292457(...TRUNCATED) |
MED-334 | Differences among total and in vitro digestible phosphorus content of plant foods and beverages. | "OBJECTIVE: Among plant foods, grain products, legumes, and seeds are important sources of phosphoru(...TRUNCATED) | what foods contain phosphorus | [0.026697784662246704,-0.012322560884058475,-0.0034737384412437677,-0.019302932545542717,-0.00071259(...TRUNCATED) | [-0.016551116481423378,0.01100252941250801,0.026595361530780792,0.014386103488504887,0.0385443456470(...TRUNCATED) | [0.017520954832434654,0.012879098765552044,-0.019120564684271812,0.07127979397773743,0.0023097165394(...TRUNCATED) |
MED-335 | Differences among total and in vitro digestible phosphorus content of meat and milk products. | "OBJECTIVE: Meat and milk products are important sources of dietary phosphorus (P) and protein. The (...TRUNCATED) | what is dp content of milk and meat | [0.02099679782986641,-0.0059110550209879875,0.0036124924663454294,-0.028039202094078064,-0.005829545(...TRUNCATED) | [0.007951387204229832,-0.0037551666609942913,0.006314519327133894,0.014387041330337524,0.00654747011(...TRUNCATED) | [0.0016359160654246807,0.02030741609632969,-0.025218840688467026,0.06805410981178284,0.0004533233877(...TRUNCATED) |
End of preview. Expand
in Data Studio
README.md exists but content is empty.
- Downloads last month
- 7